COVID-19 Outpatient Clinical Trials in Utah

November 1, 2020

A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-dose Thimerosal in Adults with Symptomatic SARS-CoV-2 Infection

Study Sponsor: Beech Tree Labs

Investigational Site: Intermountain Clinical Research, Draper, Utah

Contact: sickwithcoronavirus.com

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734tm) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

Study Sponsor: Gilead Sciences

Investigational Site: Intermountain Healthcare, Murray Utah 84107

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial

Study Sponsor: Intermountain Health Care, Inc. University of Utah, Utah Department of Health

Contacts: Intermountain Medical Center - Valerie T Aston 801 507-4606 Valerie.Aston@imail.org, University of Utah - Estelle Harris, MD 801 581 7806 (not yet recruiting)

Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19

Study Sponsor: Johns Hopkins University

Investigational Site: University of Utah, Salt Lake City, Utah 84132

Contact: Priscilla Rosen 801 213-3401 priscilla.rosen@hsc.utah.edu

Clinical-trial of COVID-19 Convalescent Plasma in Outpatients

Study Sponsor: Stanford University

Investigational Site: University of Utah, Salt Lake City, Utah 84132

Hydroxychloroquine for Outpatients with Confirmed COVID-19

Study Sponsor: University of Utah

Contact: Christina Pacchia, PhD 801 213-8735 christina.pacchia@hsc.utah.edu

Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans

Study Sponsor: University of Utah, VA Salt Lake City Health Care System

Principal Investigator: Adam P Bress, PharmD. MS University of Utah